Summary
Non-insulin-dependent diabetes mellitus (NIDDM) is normally treated by oral hypoglycaemic agents, but their use is excluded during pregnancy because of their potential teratogenic and hypoglycaemic effects on the fetus. This caveat was recently questioned as glyburide was shown to cross an isolated cotyledon in vitro in insignificant amounts. In the present study, placental transport of glyburide in vivo was examined as an indispensable step towards clinical trials. Tritiated glyburide, C14 albumin or C14-labelled diazepam were injected into 13, 9 and 11 pregnant rats, respectively and the radioactivity was measured thereafter in maternal blood and in whole fetal extracts. The ratios between radioactivity in fetal tissue to that in maternal blood for glyburide (0.535 ± 0.068) were similar to those of diazepam (0.641 ± 0.057) which readily crosses the placenta. However, they differed significantly from those for albumin (0.048 ± 0.0004) which does not cross. Moreover, glyburide in fetal tissue consistently reflected its concentration in maternal blood when measured at consecutive intervals after intravenous injection in the mother. In contrast, albumin in fetal tissue was low at all time points regardless of its levels in maternal blood when measured at different times after injection. These data suggest that glyburide crosses the placenta of pregnant rats and should therefore be considered with caution as a hypoglycaemic agent in the treatment of gestational diabetes.
Article PDF
Similar content being viewed by others
Abbreviations
- NIDDM:
-
Non-insulin-dependent diabetes mellitus
- OHA:
-
oral hypoglycaemic agents
References
Gerich JE (1989) Oral hypoglycemic agents. N Engl J Med 321: 1231–1245
London M, Gobbe S, Sach L (1990) Management of diabetes mellitus and pregnancy: a survey of obstetricians and maternal-fetal specialists. Obstet Gynecol 75: 635–640
Vaughn NSA (1987) Prescribing in pregnancy. Treatment of diabetes in pregnancy. BMJ 294: 558–560
Coustan DR (1988) Management of gestational diabetes. In: Reece EA, Coustan DR (eds) Diabetes mellitus in pregnancy. Principles and practice. Churchill Livingstone New York, p 443
Adams PAJ, Schwartz R (1968) Diagnosis and treatment: should oral hypoglycemic agents be used in pediatric and pregnant patients? Pediatrics 42: 819–823
Larsson Y, Sterky G (1960) Possible teratogenic effect of tolbutamide in a pregnant prediabetic. Lancet, 1424–1425
Schiff D, Aranda JV, Stern L (1970) Neonatal thrombocy-topenia and congenital malformations associated with administration of tolbutamide to the mother. J Pediatr 77: 457–458
Zucker P, Simon G (1968) Prolonged symptomatic neonatal hypoglycaemia associated with maternal chlorpropamide therapy. Pediatrics 42: 824–825
Kemball ML, McIver C, Milner RDG, Nourse CYH, Schiff D, Tierman JR (1970) Neonatal hypoglycaemia in infants of diabetic mothers given sulfonylurea drugs in pregnancy. Arch Dis Child 45: 696–701
Coetzee EJ, Jackson WPU (1980) Pregnancy in established non-insulin-dependent diabetics. S Afr Med J 58: 795–802
Sutherland HW, Stowers JM, Cormack JD, Bewsher PD (1973) Evaluation of chlorpropamide in chemical diabetes diagnosed during pregnancy. BMJ 3: 9–13
Stowers JM, Sutherland HW (1975) The use of sulfonyl-ureas, biguanides and insulin in pregnancy. In: Sutherland HW, Stowers JM, Persson DWM (eds) Carbohydrate metabolism in pregnancy and the newborn. Churchill Livingstone, Edinburgh, pp 205–220
Elliot BD, Langer O, Schenkers S, Johnson RF (1991) Insignificant transfer of glyburide occurs across the human placenta. Am J Obstet Gynecol 165: 807–812
Piacquadio K, Hollingsworth DR, Murphey H (1991) Effects of in-utero exposure to oral hypoglycaemic drugs. Lancet 338: 866–869
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sivan, E., Feldman, B., Dolitzki, M. et al. Glyburide crosses the placenta in vivo in pregnant rats. Diabetologia 38, 753–756 (1995). https://doi.org/10.1007/s001250050348
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/s001250050348